- Home
- HPK vs SNY Comparison
HPK vs SNY Comparison
Compare HPK & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HPK
- SNY
- Stock Information
- Founded
- HPK 2019
- SNY 1994
- Country
- HPK United States
- SNY France
- Employees
- HPK N/A
- SNY N/A
- Industry
- HPK Oil & Gas Production
- SNY Biotechnology: Pharmaceutical Preparations
- Sector
- HPK Energy
- SNY Health Care
- Exchange
- HPK Nasdaq
- SNY Nasdaq
- Market Cap
- HPK 1.5B
- SNY 116.5B
- IPO Year
- HPK N/A
- SNY N/A
- Fundamental
- Price
- HPK $10.05
- SNY $49.02
- Analyst Decision
- HPK Sell
- SNY Buy
- Analyst Count
- HPK 2
- SNY 2
- Target Price
- HPK $11.50
- SNY $62.50
- AVG Volume (30 Days)
- HPK 328.7K
- SNY 2.1M
- Earning Date
- HPK 08-04-2025
- SNY 07-24-2025
- Dividend Yield
- HPK 1.56%
- SNY 3.26%
- EPS Growth
- HPK N/A
- SNY 39.56
- EPS
- HPK 0.88
- SNY 5.45
- Revenue
- HPK $1,039,098,000.00
- SNY $48,817,552,946.00
- Revenue This Year
- HPK N/A
- SNY $3.39
- Revenue Next Year
- HPK N/A
- SNY $7.05
- P/E Ratio
- HPK $11.65
- SNY $8.99
- Revenue Growth
- HPK N/A
- SNY N/A
- 52 Week Low
- HPK $7.82
- SNY $45.80
- 52 Week High
- HPK $17.48
- SNY $60.12
- Technical
- Relative Strength Index (RSI)
- HPK 40.05
- SNY 42.20
- Support Level
- HPK $9.69
- SNY $47.64
- Resistance Level
- HPK $10.20
- SNY $48.55
- Average True Range (ATR)
- HPK 0.48
- SNY 0.65
- MACD
- HPK -0.23
- SNY 0.03
- Stochastic Oscillator
- HPK 0.60
- SNY 23.48
About HPK HighPeak Energy Inc.
HighPeak Energy Inc is an independent crude oil and natural gas company focused on the development of unconventional oil and natural gas reserves in Howard County of the Midland Basin. The company operates in a single segment, which is crude oil and natural gas development, exploration, and production in the U.S.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.